Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Antisense inhibition of survivin expression as a cancer therapeutic.

Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK.

Mol Cancer Ther. 2011 Feb;10(2):221-32. doi: 10.1158/1535-7163.MCT-10-0756. Epub 2011 Jan 7.

2.

1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.

Al-awar RS, Ray JE, Hecker KA, Huang J, Waid PP, Shih C, Brooks HB, Spencer CD, Watkins SA, Patel BR, Stamm NB, Ogg CA, Schultz RM, Considine EL, Faul MM, Sullivan KA, Kolis SP, Grutsch JL, Joseph S.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3217-20.

PMID:
15149678
3.

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.

Hamdouchi C, Keyser H, Collins E, Jaramillo C, De Diego JE, Spencer CD, Dempsey JA, Anderson BD, Leggett T, Stamm NB, Schultz RM, Watkins SA, Cocke K, Lemke S, Burke TF, Beckmann RP, Dixon JT, Gurganus TM, Rankl NB, Houck KA, Zhang F, Vieth M, Espinosa J, Timm DE, Campbell RM, Patel BK, Brooks HB.

Mol Cancer Ther. 2004 Jan;3(1):1-9.

4.

Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

Engler TA, Furness K, Malhotra S, Sanchez-Martinez C, Shih C, Xie W, Zhu G, Zhou X, Conner S, Faul MM, Sullivan KA, Kolis SP, Brooks HB, Patel B, Schultz RM, DeHahn TB, Kirmani K, Spencer CD, Watkins SA, Considine EL, Dempsey JA, Ogg CA, Stamm NB, Anderson BD, Campbell RM, Vasudevan V, Lytle ML.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2261-7.

PMID:
12824014
5.

One-step cellular caspase-3/7 assay.

Carrasco RA, Stamm NB, Patel BK.

Biotechniques. 2003 May;34(5):1064-7. No abstract available.

6.

Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene.

Rao RN, Stamm NB, Otto K, Kovacevic S, Watkins SA, Rutherford P, Lemke S, Cocke K, Beckmann RP, Houck K, Johnson D, Skidmore BJ.

Oncogene. 1999 Nov 4;18(46):6343-56.

7.

LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.

Hirsch KS, Jones CD, Audia JE, Andersson S, McQuaid L, Stamm NB, Neubauer BL, Pennington P, Toomey RE, Russell DW.

Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5277-81.

8.

Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase.

Jones CD, Audia JE, Lawhorn DE, McQuaid LA, Neubauer BL, Pike AJ, Pennington PA, Stamm NB, Toomey RE, Hirsch KS.

J Med Chem. 1993 Feb 5;36(3):421-3. No abstract available.

PMID:
8381185
9.

LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats.

Neubauer BL, Best KL, Blohm TR, Gates C, Goode RL, Hirsch KS, Laughlin ME, Petrow V, Smalstig EB, Stamm NB, et al.

Prostate. 1993;23(3):181-99.

PMID:
8234065
10.

Discovery and development of a novel class of nonsteroidal aromatase inhibitors.

Hirsch KS, Jones CD, Lindstrom TD, Stamm NB, Sutton GP, Taylor HM, Weaver DE.

Steroids. 1987 Jul-Sep;50(1-3):201-17.

PMID:
3504060
11.

Thermogenesis and weight control.

Yen TT, McKee MM, Stamm NB.

Int J Obes. 1984;8 Suppl 1:65-78.

PMID:
6152557
12.
13.

Constitutive hepatic glucokinase activity in db/db and ob/ob mice.

Yen TT, Stamm NB.

Biochim Biophys Acta. 1981 Jan 15;657(1):195-202.

PMID:
7011401
14.
15.

Hepatic insensitivity to glucagon in ob/ob mice.

Yen TT, Stamm NB, Fuller RW, Root MA.

Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):29-40.

PMID:
6254120
16.

Antihypertensive effects of fluoxetine and L-5-hydroxytryptophan in rats.

Fuller RW, Holland DR, Yen TT, Bemis KG, Stamm NB.

Life Sci. 1979 Oct 1;25(14):1237-42. No abstract available.

PMID:
316092
17.

Pergolide: a potent dopaminergic antihypertensive.

Yen TT, Stamm NB, Clemens JA.

Life Sci. 1979 Jul 16;25(3):209-15. No abstract available.

PMID:
39213
18.

Regulation of hepatic carbohydrate metabolism by FFA and acetyl-CoA: sequential feedback inhibition.

Weber G, Lea MA, Stamm NB.

Lipids. 1969 Sep;4(5):388-96. No abstract available.

PMID:
5823720
19.

Sequential feedback inhibition and regulation of liver carbohydrate metabolism through control of enzyme activity.

Weber G, Lea MA, Stamm NB.

Adv Enzyme Regul. 1968;6:101-23. No abstract available.

PMID:
5720332
20.

Regulation of gluconeogenesis and glycolysis: studies of mechanisms controlling enzyme activity.

Weber G, Lea MA, Convery HJ, Stamm NB.

Adv Enzyme Regul. 1967;5:257-300. No abstract available.

PMID:
4301791
21.

Feedback inhibition of key glycolytic enzymes in liver: action of free fatty acids.

Weber G, Convery HJ, Lea MA, Stamm NB.

Science. 1966 Dec 9;154(3754):1357-60.

PMID:
4288679
22.

Synchronous behavior pattern of key glycolytic enzymes: glucokinase, phosphofructokinase, and pyruvate kinase.

Weber G, Singhal RL, Stamm NB, Lea MA, Fisher EA.

Adv Enzyme Regul. 1966;4:59-81. Review. No abstract available.

PMID:
4295201
23.

Regulatory pattern of liver carbohydrate metabolizing enzymes: insulin as inducer of key glycolytic enzymes.

Weber G, Lea MA, Fisher EA, Stamm NB.

Enzymol Biol Clin (Basel). 1966;7(1):11-24. No abstract available.

PMID:
4288304
24.

INSULIN: INDUCER OF PYRUVATE KINASE.

WEBER G, STAMM NB, FISHER EA.

Science. 1965 Jul 2;149(3679):65-7.

PMID:
14300524
25.

HORMONAL INDUCTION AND SUPPRESSION OF LIVER ENZYME BIOSYNTHESIS.

WEBER G, SINGHAL RL, STAMM NB, SRIVASTAVA SK.

Fed Proc. 1965 May-Jun;24:745-54. No abstract available.

PMID:
14344235
26.

Regulation of enzymes involved in gluconeogenesis.

Weber G, Singhal RL, Stamm NB, Fisher EA, Mentendiek MA.

Adv Enzyme Regul. 1964;2:1-38. No abstract available.

PMID:
5863087
27.

ACTINOMYCIN: INHIBITION OF CORTISONE-INDUCED SYNTHESIS OF HEPATIC GLUCONEOGENIC ENZYMES.

WEBER G, SINGHAL RL, STAMM NB.

Science. 1963 Oct 18;142(3590):390-2.

PMID:
14056705

Supplemental Content

Loading ...
Support Center